Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

Lantern Pharma CEO Panna Sharma joined Steve Darling from Proactive to share news the company has presented preclinical data on the potency of drug candidate LP-284 for mantle cell lymphoma and several other non-Hodgkin’s lymphomas using its RADR technology.

Sharma talks more about the results and how LP-284 is the next generation acylfulvene that has a synthetically lethal mechanism of action in cancers with impaired DNA damage repair pathway genes.

#proactiveinvestors #Laternpharmainc #nasdaq #LTRN #cancer

You might like

© 2022 The Latest StockMarket News and Interviews